← The SEC Ephemeris: the whole map
Mylan GmbH insulin glargine
In the graph: all 2 documents (9 pages).
- Application
- NDA 210605
- Ticker
- Mylan GmbH
- Product
- insulin glargine
- Disease area
- Not yet classified
- Response path
- Not yet classified
- Complete Response Letters
- August 28, 2019 · May 17, 2018
From FDA letters and SEC filings. Not investment or medical advice.